These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 32943072)

  • 21. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors.
    Gentzler R; Hall R; Kunk PR; Gaughan E; Dillon P; Slingluff CL; Rahma OE
    Immunotherapy; 2016 May; 8(5):583-600. PubMed ID: 27140411
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combining Radiotherapy and Immunotherapy in Lung Cancer: Can We Expect Limitations Due to Altered Normal Tissue Toxicity?
    Wirsdörfer F; de Leve S; Jendrossek V
    Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30577587
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
    Sun X; Roudi R; Dai T; Chen S; Fan B; Li H; Zhou Y; Zhou M; Zhu B; Yin C; Li B; Li X
    BMC Cancer; 2019 Jun; 19(1):558. PubMed ID: 31182061
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis.
    Duan J; Cui L; Zhao X; Bai H; Cai S; Wang G; Zhao Z; Zhao J; Chen S; Song J; Qi C; Wang Q; Huang M; Zhang Y; Huang D; Bai Y; Sun F; Lee JJ; Wang Z; Wang J
    JAMA Oncol; 2020 Mar; 6(3):375-384. PubMed ID: 31876895
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy.
    Kim J; Hong J; Lee J; Fakhraei Lahiji S; Kim YH
    J Control Release; 2021 Apr; 332():109-126. PubMed ID: 33571549
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer.
    Hu ZI; Ho AY; McArthur HL
    Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):153-164. PubMed ID: 28816141
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Programmed cell death ligand-1: A dynamic immune checkpoint in cancer therapy.
    Kalim M; Iqbal Khan MS; Zhan J
    Chem Biol Drug Des; 2020 Jun; 95(6):552-566. PubMed ID: 32166894
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
    McArthur HL; Page DB
    Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radiation Recall Pneumonitis Anticipates Bilateral Immune-Induced Pneumonitis in Non-Small Cell Lung Cancer.
    Torresan S; Zussino G; Cortiula F; Follador A; Fasola G; Girometti R; Cereser L
    J Clin Med; 2023 Feb; 12(4):. PubMed ID: 36835802
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PD-1/PD-L1 blockade in cervical cancer: current studies and perspectives.
    Wang Y; Li G
    Front Med; 2019 Aug; 13(4):438-450. PubMed ID: 30826965
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pneumonitis From Anti-PD-1/ PD-L1 Therapy.
    Balaji A; Verde F; Suresh K; Naidoo J
    Oncology (Williston Park); 2017 Oct; 31(10):739-46, 754. PubMed ID: 29083466
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer.
    Kurozumi S; Fujii T; Matsumoto H; Inoue K; Kurosumi M; Horiguchi J; Kuwano H
    Med Mol Morphol; 2017 Dec; 50(4):185-194. PubMed ID: 28936553
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PD-1/PD-L1 and immunotherapy for pancreatic cancer.
    Feng M; Xiong G; Cao Z; Yang G; Zheng S; Song X; You L; Zheng L; Zhang T; Zhao Y
    Cancer Lett; 2017 Oct; 407():57-65. PubMed ID: 28826722
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Radiation recall pneumonitis caused by erlotinib after palliative definitive radiotherapy.
    Onal C; Abali H; Koc Z; Kara S
    Onkologie; 2012; 35(4):191-4. PubMed ID: 22488089
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Immunotherapy with PD-1 and PD-L1 inhibitors for prostate cancer].
    Huang L; He J
    Zhonghua Nan Ke Xue; 2020 Nov; 26(10):944-948. PubMed ID: 33382229
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?
    Chae YK; Pan A; Davis AA; Raparia K; Mohindra NA; Matsangou M; Giles FJ
    Clin Lung Cancer; 2016 Sep; 17(5):350-361. PubMed ID: 27137346
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Radiation Recall Pneumonitis After Treatment With Checkpoint Blockade Immunotherapy: A Case Series and Review of Literature.
    Riviere P; Sumner W; Cornell M; Sandhu A; Murphy JD; Hattangadi-Gluth J; Bruggeman A; Kim SS; Randall JM; Sharabi AB
    Front Oncol; 2021; 11():662954. PubMed ID: 33996587
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Severe Immune-Related Pneumonitis With PD-1 Inhibitor After Progression on Previous PD-L1 Inhibitor in Small Cell Lung Cancer: A Case Report and Review of the Literature.
    Liang X; Guan Y; Zhang B; Liang J; Wang B; Li Y; Wang J
    Front Oncol; 2019; 9():1437. PubMed ID: 31921686
    [No Abstract]   [Full Text] [Related]  

  • 40. Treatment-related toxicities of immune checkpoint inhibitors in advanced cancers: A meta-analysis.
    Man J; Ritchie G; Links M; Lord S; Lee CK
    Asia Pac J Clin Oncol; 2018 Jun; 14(3):141-152. PubMed ID: 29349927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.